| | Business Summary | | Chiron
Corporation
is
a
biotechnology
company
that
applies
leading
scientific
approaches
to
discover
and
develop
innovative
healthcare
products
to
prevent
and
treat
cancer
and
infection.
The
Company
brings
products
to
the
global
healthcare
market
through
collaborations
with
major
healthcare
companies
and
through
three
growing
businesses:
biopharmaceuticals,
vaccines,
and
blood
testing.
Chiron
acquired
PathoGenesis
Corporation,
a
biotechnology
company
developing
drugs
to
treat
infectious
diseases,
particularly
serious
lung
infections,
where
there
is
significant
need
for
improved
therapy.
The
Company
also
established
an
alliance
with
Novartis
AG,
a
life
sciences
company
headquartered
in
Basel,
Switzerland. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Chiron
Corp.
is
a
biotechnology
company
that
is
developing
products
for
preventing
and
treating
cancer,
infectious
diseases
and
cardiovascular
disease.
For
the
six
months
ended
6/30/01,
total
revenues
rose
14%
to
$520.8
million.
Net
income
from
continuing
operations
fell
19%
to
$78.7
million.
Revenues
reflect
an
increase
in
royalty
and
license
fees
and
higher
net
product
sales.
Earnings
were
offset
by
increased
research
and
development
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Sean Lance, 53
Chairman,
Pres, CEO | $2.1M | -- | William Green, 56
Sr.
VP, Gen. Counsel and Sec. | 743K | $3.9M | James Sulat, 50
VP
and CFO | 620K | -- | Rajen Dalal, 47
VP
of Corp. Devel. and Pres- Chiron Blood Testing | 2.8M | -- | David Smith, 41
VP
and Controller | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/c/chir.gif)